Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Investment House LLC

Investment House LLC lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 161,574 shares of the medical research company’s stock after selling 6,280 shares during the period. Investment House LLC’s holdings in Edwards Lifesciences were worth $11,961,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the period. State Street Corp raised its position in shares of Edwards Lifesciences by 1.0% in the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after acquiring an additional 256,538 shares during the period. Geode Capital Management LLC raised its position in shares of Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after acquiring an additional 284,918 shares during the period. Fisher Asset Management LLC raised its position in shares of Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after acquiring an additional 696,965 shares during the period. Finally, Jennison Associates LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $555,939,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on EW shares. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Truist Financial reissued a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $79.95.

Insider Transactions at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 6,164 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. This represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $70.31 on Wednesday. The firm has a 50 day simple moving average of $71.61 and a 200-day simple moving average of $70.35. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market cap of $41.33 billion, a price-to-earnings ratio of 10.09, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.